@文章{信息:doi/10.2196/33240，作者="Mudaranthakam, Dinesh Pal和Gajewski, Byron和Krebill, Hope和Coulter, James和施普林格，Michelle和Calhoun, Elizabeth和Hughes, Dorothy和Mayo, Matthew和Doolittle, Gary"，标题="临床试验参与的障碍:农村和城市参与者之间的比较研究"，期刊="JMIR癌症"，年="2022"，月="Apr"，日="21"，卷="8"，数="2"，页数="e33240"，关键词="农村居民;临床试验;筛选;癌症;病人;肺癌;卫生政策流行病学;癌症患者;电子筛选日志;背景:国家临床试验网络项目在所有国家癌症研究所指定的癌症中心进行2期或3期治疗试验。 Participant accrual across these clinical trials is a critical factor in deciding their success. Cancer centers that cater to rural populations, such as The University of Kansas Cancer Center, have an additional responsibility to ensure rural residents have access and are well represented across these studies. Objective: There are scant data available regarding the factors that act as barriers to the accrual of rural residents in these clinical trials. This study aims to use electronic screening logs that were used to gather patient data at several participating sites in The Kansas University of Cancer Center's Catchment area. Methods: Screening log data were used to assess what clinical trial participation barriers are faced by these patients. Additionally, the differences in clinical trial participation barriers were compared between rural and urban participating sites. Results: Analysis revealed that the hospital location rural urban category, defined as whether the hospital was in an urban or rural setting, had a medium effect on enrolment of patients in breast cancer and lung cancer trials (Cohen d=0.7). Additionally, the hospital location category had a medium effect on the proportion of recurrent lung cancer cases at the time of screening (d=0.6). Conclusions: In consideration of the financially hostile nature of cancer treatment as well as geographical and transportation barriers, clinical trials extended to rural communities are uniquely positioned to alleviate the burden of nonmedical costs in trial participation. However, these options can be far less feasible for patients in rural settings. Since the number of patients with cancer who are eligible for a clinical trial is already limited by the stringent eligibility criteria required of such a complex disease, improving accessibility for rural patients should be a greater focus in health policy. ", issn="2369-1999", doi="10.2196/33240", url="https://cancer.www.mybigtv.com/2022/2/e33240", url="https://doi.org/10.2196/33240", url="http://www.ncbi.nlm.nih.gov/pubmed/35451964" }